Adjuvant chemotherapy less effective in elderly CRC patients

A subgroup analysis of the TOSCA trial showed elderly colorectal cancer (CRC) patients (≥70 years) to benefit less from adjuvant chemotherapy compared with younger patients. TOSCA is 1 of the 6 randomised, phase 3 clinical trials of the IDEA consortium, demonstrating non-inferiority of 3 months adjuvant chemotherapy as compared with 6 months chemotherapy in patients with stage III colon cancer [1]. However, a reduced benefit of adjuvant chemotherapy for patients over the age of 70 years is suggested. Therefore, a subgroup analysis of TOSCA was performed [2]. Primary endpoint of this subgroup analysis was relapse-free interval (RFI), defined as time from randomisation to relapse or last disease evaluation. In TOSCA, 2,360 patients with stage III disease were enrolled: 1,667 aged <70 (‘younger patients’) and 693 aged ≥70 (‘elderly patients’). The elderly patients had an ECOG performance status more often equal to ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 25 November, 202024 November, 2020